Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by InnoCare Pharma

< Previous 1 2 3 Next >
News headline image
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
From InnoCare Pharma
Via GlobeNewswire
News headline image
Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
From InnoCare Pharma
Via GlobeNewswire
News headline image
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
From InnoCare Pharma
Via GlobeNewswire
News headline image
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of Orelabrutinib in Australia
From InnoCare Pharma
Via GlobeNewswire
News headline image
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
From InnoCare Pharma
Via GlobeNewswire
News headline image
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Key Developments of Critical Clinical Studies
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
From InnoCare Pharma
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.